ERBB2 and breast carcinoma: Applying the Breast Cancer Gene-Expression Miner v4.7 resource, which integrated almost all BC data comprising DNA microarrays (n = 11,359, most of which were obtained from the GEO dataset) and RNA-seq (n = 4712, TCGA data), we validated the over-expression of CEMIP in BC and the TP53-mutant group (Figures 1D,F) and found higher expression of CEMIP in basal-like/TNBC and HER2+ BC compared with luminal BC (Figure 1D).